[45, 46, 47] In addition, T‐cell therapy targeting LMP1 has shown promising efficacy in EBV‐associated lymphomas,[48, 49] including a recent in vivo CAR‐T investigation of NKTCL.[50]. Here, PDLIM7 is linked to lymphoma.